Graeme Currie
Corporate Officer/Principal chez PASITHEA THERAPEUTICS CORP.
Fortune : - $ au 31/03/2024
Profil
Graeme Martin Currie is currently the Chief Development Officer at Pasithea Therapeutics Corp.
He previously held positions as the Chief Executive Officer at Alpha-5 Integrin LLC, Director-Clinical Research at Gilead Sciences, Inc., Vice President-Clinical Operations at PDL BioPharma, Inc., Chief Operating Officer at Rainier Therapeutics, Inc., Chief Development Officer at Tolerion, Inc., and Chief Development Officer at Lytix Biopharma AS.
Dr. Currie obtained a doctorate degree from the University of Aston.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 23/03/2024 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Graeme Currie
| Sociétés | Poste | Début |
|---|---|---|
| PASITHEA THERAPEUTICS CORP. | Corporate Officer/Principal | 01/06/2022 |
Anciens postes connus de Graeme Currie
| Sociétés | Poste | Fin |
|---|---|---|
| LYTIX BIOPHARMA | Corporate Officer/Principal | 01/06/2023 |
Alpha-5 Integrin LLC
 Alpha-5 Integrin LLC Pharmaceuticals: MajorHealth Technology Part of Pasithea Therapeutics Corp., Alpha-5 Integrin LLC is a private company that develops monoclonal antibody for the treatment of amyotrophic lateral sclerosis and neurodegenerative diseases. The company is based in South San Francisco, CA. The CEO of the company is Graeme Currie. Alpha-5 Integrin was acquired by Pasithea Therapeutics Corp. on June 22, 2022 for $3.29 million. | Chief Executive Officer | 01/06/2022 |
Tolerion, Inc.
 Tolerion, Inc. Pharmaceuticals: MajorHealth Technology Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA. | Corporate Officer/Principal | 01/01/2021 |
Rainier Therapeutics, Inc.
 Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Chief Operating Officer | 01/01/2019 |
| PDL BIOPHARMA, INC. | Chief Tech/Sci/R&D Officer | - |
Formation de Graeme Currie
| University of Aston | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| GILEAD SCIENCES, INC. | Health Technology |
| LYTIX BIOPHARMA | Health Technology |
| Entreprise privées | 5 |
|---|---|
PDL BioPharma, Inc.
 PDL BioPharma, Inc. BiotechnologyHealth Technology PDL BioPharma, Inc. engages in the business of developing innovative therapeutics and healthcare technologies. It operates under the Medical Devices and Income Generating Assets segments. The Medical Devices segment focuses on the sale and lease of the LENSAR laser system which includes equipment, patient interface devices, procedure licenses, training, installation, warranty, and maintenance agreements. The Income Generating Assets segment offers notes and other long-term receivables; royalty rights, hybrid notes, and royalty receivables; equity investments; and royalties from issued patents covering the humanization of antibodies. The company was founded by Cary L. Queen and Laurence Jay Korn in 1986 and is headquartered in Reno, NV. | Health Technology |
Rainier Therapeutics, Inc.
Rainier Therapeutics, Inc. BiotechnologyHealth Technology Rainier Therapeutics, Inc. operates as a biotechnology company that develops a targeted biologic for the potential treatment of metastatic bladder cancer. It provides Vofatamab, an antibody that is focused on the fibroblast growth factor of bladder and other cancer. The company was founded by Stephen Lau and is headquartered in San Leandro, CA. | Health Technology |
Tolerion, Inc.
Tolerion, Inc. Pharmaceuticals: MajorHealth Technology Tolerion, Inc. operates as a clinical-stage biopharmaceutical firm. It develops and commercializes therapeutics. The firm provides TOL-3034 and TOL-3052 to treat myasthenia gravis and neuromyelitis optica. The company was founded by Lawrence J. Steinman and is headquartered in South San Francisco, CA. | Health Technology |
| Pasithea Therapeutics Corp. | |
Alpha-5 Integrin LLC
Alpha-5 Integrin LLC Pharmaceuticals: MajorHealth Technology Part of Pasithea Therapeutics Corp., Alpha-5 Integrin LLC is a private company that develops monoclonal antibody for the treatment of amyotrophic lateral sclerosis and neurodegenerative diseases. The company is based in South San Francisco, CA. The CEO of the company is Graeme Currie. Alpha-5 Integrin was acquired by Pasithea Therapeutics Corp. on June 22, 2022 for $3.29 million. | Health Technology |
